A5088648956- Ocular Surface and Contact Lens
- Allergic Rhinitis and Sensitization
- Mast cells and histamine
- Contact Dermatitis and Allergies
- Glaucoma and retinal disorders
- DNA Repair Mechanisms
- Intraocular Surgery and Lenses
- DNA and Nucleic Acid Chemistry
- Olfactory and Sensory Function Studies
- Multiple Myeloma Research and Treatments
- Retinal Diseases and Treatments
- Carcinogens and Genotoxicity Assessment
- Corneal surgery and disorders
- Ocular Infections and Treatments
- Receptor Mechanisms and Signaling
- Urticaria and Related Conditions
- Polyomavirus and related diseases
- Retinal Development and Disorders
- Retinal and Optic Conditions
- Angiogenesis and VEGF in Cancer
- Chemical Synthesis and Analysis
- Retinal and Macular Surgery
- Ophthalmology and Visual Impairment Studies
- Retinopathy of Prematurity Studies
- Protein Degradation and Inhibitors
LabCorp (United States)
2023-2024
Oxford University Hospitals NHS Trust
2021
Bausch Health (United States)
2018-2020
Bausch Health (Canada)
2020
Manhattan Eye, Ear and Throat Hospital
2018
Anthera Pharmaceuticals (United States)
2009-2012
ENT and Allergy
2010
Genaera (United States)
2002-2004
Titan Pharmaceuticals (United States)
2002
Georgetown University Medical Center
1997-1999
Squalamine, an endogenous molecule found in the liver and other tissues of Squalus acanthias, has antibiotic properties causes changes endothelial cell shape. The latter suggested that its potential targets might include transport proteins control volume or effect purified squalamine was examined on cloned Na+/H+ exchanger isoforms NHE1, NHE2, NHE3 stably transfected PS120 fibroblasts. Squalamine (1-h pretreatment) decreased maximal velocity rabbit a concentration-dependent manner (13, 47,...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTDeoxyribonucleic acid excision repair in chromatin after ultraviolet irradiation of human fibroblasts cultureJ. I. Williams and E. C. FriedbergCite this: Biochemistry 1979, 18, 3965–3972Publication Date (Print):September 4, 1979Publication History Published online1 May 2002Published inissue 4 September 1979https://pubs.acs.org/doi/10.1021/bi00585a019https://doi.org/10.1021/bi00585a019research-articleACS PublicationsRequest reuse permissionsArticle...
The incidence of pyrimidine dimer formation and the kinetics DNA repair in African green monkey kidney CV-l cells after ultraviolet (UV) irradiation were studied by measuring survival, T4 endonuclease V-sensitive sites, fraction dimers acid-insoluble as determined thin layer chromatography (TLC), replication.CV-1 exhibit a survival curve with extrapolation number n -7.8 Do = 2.5 J/m2.Pyrimidine lost from acid- insoluble more slowly than endonuclease-sensitive sites or new bases incorporated...
Purpose To determine if systemically administered squalamine lactate, a novel aminosterol with antineoplastic and antiangiogenic activity, inhibits the development of experimental choroidal neovascularization membranes (CNVMs) induced by laser trauma in rat model. Methods Twenty anesthetized male Brown-Norway rats received series 8 krypton red lesions per eye (647 nm, 0.05 second, 50 μm, 150 mW). One half animals an intraperitoneal injection other one 5% dextrose water, all performed masked...
Purpose To investigate the effect of squalamine, an antiangiogenic aminosterol, in experimental model iris neovascularization. Methods Iris neovascularization was created cynomolgus monkeys by occluding retinal veins with argon laser and inducing persistent hypotony a central corneal suture. Twenty-four eyes were treated three groups. In Group 1, four injected intravitreally 3 μg/0.1 mL squalamine balanced saline solution (controls) immediately after vein occlusion (day 1); injections...
Purpose: To examine the pooled per-protocol ocular end points from two conjunctival allergen challenge (CAC) clinical trials of dual-action antihistamine bepotastine besilate ophthalmic solution (BBOS) 1.5%. Methods: Two Phase III, placebo-controlled, double-masked, randomized were conducted at a total six separate centers using CAC model allergic conjunctivitis. The same study design was employed for both trials, with subjects randomly assigned to either BBOS 1.5% (n=78) or placebo (n=79)...
This clinical trial evaluated the safety and effectiveness of bepotastine besilate ophthalmic solutions 1.0% 1.5% compared with placebo for treatment ocular itching conjunctival hyperemia (redness) using allergen challenge (CAC) model allergic conjunctivitis when dosed 16 h before a CAC test.Subjects history were assigned to receive or solution in single-center, randomized, placebo-controlled trial. Eligible subjects (n=107) aged 10 years older who had reproducible positive reaction enrolled...
Allergic conjunctivitis (AC) affects an estimated 20% of the population in Western world, with a large fraction suffering due to seasonal or perennial allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, dual-acting histamine (H(1)) receptor antagonist and mast cell stabilizer, is indicated for itching associated AC. This study was designed evaluate efficacy safety BBOS 1.5% reducing ocular AC subjects enrolled natural exposure trial. Eligible multicenter, double-masked,...